Navigation Links
Gleevec gets hopeful results

The Food and Drug Administration approved the drug, Gleevec, for the treatment of chronic myelogenous leukemia, a form of cancer that affects about 4,500 people in the USA each year. A study supports Gleevec's image as a potential cure for this kind of cancer, which, although cases are rare, can be deadly. //

A new study adds to the evidence suggesting that a heavily publicized drug treatment for a type of leukemia may allow patients to live longer than expected. Experts say the drug, made by Novartis Pharmaceuticals also holds promise for the treatment of lung cancer, prostate cancer and a form of stomach cancer.

In the longest study of the drug so far, researchers studied 532 patients with chronic leukemia. They all had received the standard drug, interferon, but after six months their cancer had gotten worse. The patients were switched to Gleevec, which they took once a day. After 18 months, the researchers could find no visible sign of the genetic abnormality that causes the disease in 41% of the patients.

That genetic flaw leads to the production of a protein that allows white cells in the blood and in the bone marrow to run out of control. Gleevec works by blocking the action of that protein.

Page: 1

Related medicine news :

1. Gleevec for Lung Disease
2. "Miracle" Cancer Drug Gleevec Can be Toxic to the Heart
3. Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors
4. Artificial disc looks hopeful
5. Experimental treatment for Ebola Virus Shows promising results in mice
6. IVF results may be affected by stress and other related factors
7. New dosage of medicine gets more results in neuroblastoma
8. Caffeine can interfere with PET scan results
9. Mouth wash samples to predict bone marrow transplant results
10. PET scans can detect the results of cognitive behavior therapy
11. Induced abortion results in years of trauma.
Post Your Comments:

(Date:11/28/2015)... PITTSBURGH, PA (PRWEB) , ... November 28, 2015 , ... ... to the creativity of two inventors, one from Lakewood, New Jersey and the other ... They developed the patent-pending PROTECTOR to save the expense of having to replace NuvaRings ...
(Date:11/28/2015)... CA (PRWEB) , ... November 28, 2015 , ... Pixel ... fully customizable media panels to choose from, the possibilities are endless. Users have full ... more. With the ProPanel: Pulse masking effects, users are sure to get heads to ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... University of Toronto and the University of British Columbia suggested that laws requiring bicyclists ... The article explains that part of the reason for the controversial conclusion is that, ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced ... offering customers 10% off of their purchase of lice treatment product. In addition, customers ... According to a company spokesperson. “Finding lice is a sure way to ruin the ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... 26, 2015 ) ... Administration of High Viscosity Drugs" report to ... announced the addition of the "Self Administration ... offering. --> Research and Markets ( ... "Self Administration of High Viscosity Drugs" ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) ...
Breaking Medicine Technology: